Biosimilars: The Eylea Loss-of-Exclusivity Case | Policy & Market Intelligence

Description

List of Tables

In September 2025, three of the best-known biologics on the Japanese market - Eylea, Actemra, and Simponi - met their first biosimilar competitors in the same listing wave. Of the three, aflibercept is the case that matters most. Eylea anchors retinal practice in Japan, a country whose aging population sustains one of the world's heaviest intravitreal-injection workloads, and whose ophthalmology societies have historically been cautious about switching stable patients. Fuji Pharma brought Alvotech's biosimilar to market as the first Eylea biosimilar approved and launched in Japan, with Samsung Bioepis, Celltrion, and Sam Chun Dang close behind. The contest that followed is being fought on several fronts at once. Regeneron and Bayer pursued patent enforcement, including an injunction filing in Osaka and patent-linkage litigation carried to the Supreme Court, before a 2026 settlement with Alvotech defined the terms of a full-indication launch. Bayer answered commercially with an authorized biologic - a bio-AG - distributed with Santen and NHI-listed in December 2025, an originator counter-move with few precedents anywhere. Policymakers, meanwhile, are debating AG-parity pricing, a mechanism that would reset the price relationship between originator, authorized biologic, and biosimilar, and with it the economics of every future loss-of-exclusivity wave. What remains unresolved is how quickly Japanese retina specialists will move: indication scopes differ by entrant, dosing-regimen patents complicate label parity, and the bio-AG blurs the line biosimilars are supposed to exploit. This report reconstructs the Eylea case in full - approvals, listings, indication coverage, the litigation docket, the settlement structure, NHI price formation, and the bio-AG maneuver - and then asks what it predicts for the next wave of Japanese biologic expiries, from denosumab and ustekinumab toward dupilumab. It is written for biosimilar entrants calibrating Japan strategy, originator lifecycle teams preparing their own defenses, wholesalers and hospital purchasers, and investors pricing the theme. Readers come away with a case study that functions as a playbook: who did what, in what order, under which rules, and which decisions are still open.

Scope and Coverage

The report covers the aflibercept, tocilizumab, and golimumab biosimilar waves in Japan, the surrounding litigation and settlements, NHI pricing and AG-parity proposals, and the forward LOE calendar, with US and EU launches used as comparators.

Report Highlights

Complete chronology of the 2025-2026 Eylea, Actemra, and Simponi biosimilar listings
Entrant-by-entrant profiles: Alvotech/Fuji Pharma, Samsung Bioepis, Celltrion, Sam Chun Dang, and Fresenius Kabi
The Osaka injunction, Supreme Court patent-linkage case, and the 2026 Alvotech settlement explained
Bayer and Santen's bio-AG counter-launch and the AG-parity pricing debate
NHI price-formation mechanics for biosimilars and originator repricing exposure
Read-through framework for upcoming denosumab, ustekinumab, and dupilumab LOE waves

Product Code: JPH-096

Table of Content

1. Executive Summary

2. Biosimilars: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

Fuji Pharma (JP) - commercializes Alvotech's aflibercept biosimilar, the first Eylea biosimilar approved and launched in Japan
Alvotech (IS) - developer of AVT06; 2026 global settlement with Regeneron/Bayer enabling Japan launch and full indications
Bayer (DE) - Eylea originator in Japan via Bayer Yakuhin; bio-AG counter-launch NHI-listed Dec 2025
Santen (JP) - commercialization partner for Bayer's Eylea bio-AG in Japan
Regeneron (US) - Eylea originator; patent enforcement including the Osaka injunction filing and the Alvotech settlement
Samsung Bioepis (KR) - SB15 aflibercept biosimilar approved in Japan with narrowed indications; patent-linkage litigation pursued through the Supreme Court
Celltrion (KR) - Eydenzelt (CT-P42) aflibercept biosimilar approved in Japan Mar 2026 within a rolling Japan launch wave
Sam Chun Dang (KR) - SCD411 aflibercept biosimilar approved in Japan in vial and prefilled-syringe formats
Sandoz (CH) - Enzeevu aflibercept biosimilar in the US and EU; global benchmark for retina biosimilar entry
Amgen (US) - Pavblu, first US aflibercept biosimilar launch under settlement
Fresenius Kabi (DE) - Tyenne tocilizumab biosimilar in the Actemra cohort NHI-listed in Japan Nov 2025
Henlius (CN) - HLX04-O aflibercept biosimilar in Phase 3; China retina contender
Bio-Thera (CN) - BAT5906 aflibercept biosimilar in late-stage China development
Nichi-Iko (JP) - domestic generics and biosimilars maker active in the 2025-2026 listing wave

Product Code: JPH-096

List of Tables

Table 1. Japan biosimilar approval timeline by molecule and reference brand, 2009-2026
Table 2. NHI price-formation rules for biosimilars: launch pricing, premium categories, and revision mechanics
Table 3. Biologics facing loss of exclusivity in Japan, 2025-2028, by molecule and originator
Table 4. Ophthalmology anti-VEGF landscape in Japan: Eylea, Vabysmo, Lucentis, and biosimilar entrants
Table 5. MHLW biosimilar-promotion instruments: targets, hospital incentives, and formulary guidance
Table 6. Eylea franchise structure in Japan: roles of Bayer Yakuhin and Santen
Table 7. Alvotech AVT06 and Fuji Pharma: Japan approval scope and launch arrangements (2025)
Table 8. Samsung Bioepis SB15: Japan approval and narrowed indication scope
Table 9. Celltrion Eydenzelt (CT-P42): Japan approval and launch sequence (2026)
Table 10. Sam Chun Dang SCD411: vial and prefilled-syringe presentations approved in Japan
Table 11. Indication coverage by aflibercept biosimilar entrant versus the Eylea label
Table 12. China retina contenders relevant to Japan: Henlius HLX04-O and Bio-Thera BAT5906 development status
Table 13. Global aflibercept benchmarks: Sandoz Enzeevu and Amgen Pavblu entry structures in the US and EU
Table 14. Marketing-authorization and distribution arrangements for aflibercept biosimilars in Japan
Table 15. Substitution and switching rules applicable to ophthalmic biosimilars in Japanese practice
Table 16. Prefilled-syringe versus vial competition in Japanese intravitreal workflow
Table 17. Aflibercept patent estate in Japan: composition, formulation, dosing-regimen, and device families
Table 18. Osaka District Court injunction proceedings: parties, claims, and procedural status
Table 19. Patent-linkage litigation to the Supreme Court: procedural history and issues under review
Table 20. Alvotech settlement with Regeneron and Bayer (2026): scope for Japan launch and indications
Table 21. US and EU aflibercept settlement structures and their read-through to Japan
Table 22. Dosing-regimen patents and the extended-interval label question for aflibercept biosimilars
Table 23. Tocilizumab biosimilars in Japan: Fresenius Kabi Tyenne listing (2025) and the Actemra cohort
Table 24. Golimumab (Simponi) biosimilar pipeline and Japan entry status
Table 25. Rheumatology biosimilar adoption framework: society guidance and hospital formularies
Table 26. Originator lifecycle responses in the Actemra cohort: subcutaneous formulations and devices
Table 27. Wholesaler and distribution arrangements across the 2025-2026 biosimilar listing wave
Table 28. Bayer bio-AG strategy: authorized-biologic launch with Santen and NHI listing (2025)
Table 29. AG-parity pricing proposal: mechanism, policy discussion, and stakeholder positions
Table 30. NHI repricing exposure of Eylea following biosimilar entry: applicable rule categories
Table 31. Originator defense precedents in Japan: infliximab and etanercept biosimilar waves
Table 32. Biosimilar premium and re-examination-period considerations for the aflibercept class
Table 33. Chuikyo treatment of the ophthalmology biologics budget in recent reform rounds
Table 34. Hospital purchasing economics for intravitreal anti-VEGF agents
Table 35. Retina-society guidance and physician-survey evidence on biosimilar switching
Table 36. Nichi-Iko and domestic makers in the 2025-2026 listing wave: portfolio positions
Table 37. Upcoming Japanese biologic LOEs: denosumab, ustekinumab, and dupilumab watchlist
Table 38. Korean makers' Japan strategies: Samsung Bioepis and Celltrion portfolio sequencing
Table 39. China-origin biosimilar developers with Japan potential: Henlius and Bio-Thera programs
Table 40. Development-partnership archetypes linking overseas biosimilar developers to Japanese MAHs
Table 41. Manufacturing and supply arrangements behind Japan-approved aflibercept biosimilars
Table 42. PMDA comparability and extrapolation expectations for ophthalmic biosimilars
Table 43. Registry and pharmacovigilance obligations for biosimilar MAHs in Japan
Table 44. Adoption scenarios for aflibercept biosimilars in Japanese retina practice: variables and assumptions
Table 45. Scenario grid for bio-AG versus biosimilar price relationships under AG-parity pricing
Table 46. Questions the Eylea case raises for the ustekinumab and dupilumab LOE waves
Table 47. Competitive-position matrix for aflibercept biosimilar entrants in Japan
Table 48. Wholesaler and clinic purchasing dynamics shaping biosimilar share capture
Table 49. International lessons for Japan from US and EU aflibercept launches
Table 50. Timeline of Eylea LOE events in Japan: approvals, listings, litigation, and policy actions, 2024-2026

List of Figures

Figure 1. Japan biologics loss-of-exclusivity calendar, 2025-2030
Figure 2. Aflibercept competitive map in Japan: originator, bio-AG, and biosimilar entrants
Figure 3. NHI price-formation flow for a first biosimilar listing
Figure 4. Eylea franchise architecture in Japan: Bayer, Santen, and the distribution channel
Figure 5. Aflibercept patent-estate map by patent family and challenge pathway
Figure 6. Litigation timeline for aflibercept biosimilars in Japan, 2024-2026
Figure 7. Settlement-to-launch pathway illustrated by the Alvotech agreement (2026)
Figure 8. Indication-coverage comparison across aflibercept biosimilars
Figure 9. Prefilled-syringe versus vial positioning in the intravitreal workflow
Figure 10. Retina clinic decision tree for treatment-naive versus switched patients
Figure 11. Bio-AG counter-launch mechanics: how an authorized biologic enters the NHI list
Figure 12. AG-parity pricing proposal: mechanics and expected market behavior
Figure 13. Biosimilar price-gap pathway under successive NHI revisions
Figure 14. Adoption-curve framework for ophthalmic biosimilars in Japan
Figure 15. Tocilizumab and golimumab biosimilar landscape map
Figure 16. Rheumatology versus ophthalmology adoption drivers compared
Figure 17. Wholesaler channel map for the 2025-2026 biosimilar wave
Figure 18. Hospital formulary decision process for intravitreal biosimilars
Figure 19. Originator lifecycle-defense playbook schematic
Figure 20. Adoption trajectories of earlier Japanese biosimilar classes
Figure 21. Korean entrants' Japan sequencing: Samsung Bioepis and Celltrion portfolios
Figure 22. China-origin aflibercept programs and potential Japan pathways
Figure 23. Partnership archetypes linking overseas developers to Japanese MAHs
Figure 24. Manufacturing network behind Japan-listed aflibercept biosimilars
Figure 25. PMDA comparability evidence package for an ophthalmic biosimilar
Figure 26. Extrapolation logic from studied indications to the broader Eylea label
Figure 27. Pharmacovigilance and registry obligations across the biosimilar cohort
Figure 28. Society guidance landscape for retinal biosimilar use in Japan
Figure 29. Switch-versus-start patient segmentation across nAMD, DME, and RVO
Figure 30. Chuikyo biosimilar-promotion instruments and their market touchpoints
Figure 31. Scenario tree for Eylea franchise evolution after biosimilar entry
Figure 32. Scenario tree for biosimilar uptake under parity-pricing adoption
Figure 33. Read-through matrix from the Eylea case to denosumab and ustekinumab
Figure 34. Read-through matrix from the Eylea case to dupilumab and later LOEs
Figure 35. Competitive-position map of aflibercept biosimilar entrants
Figure 36. US and EU aflibercept launch sequencing as a comparator set
Figure 37. Japan patent-linkage system operation: process map
Figure 38. Supreme Court proceedings in the aflibercept dispute: issue map
Figure 39. Dosing-regimen label competition and extended-interval positioning
Figure 40. Device and presentation differentiation in intravitreal delivery
Figure 41. NHI listing sequence in the 2025-2026 biosimilar wave
Figure 42. Stakeholder map: payers, societies, wholesalers, MAHs, and originators
Figure 43. Risk register for biosimilar entrants in Japanese ophthalmology
Figure 44. Risk register for originators facing the Eylea LOE
Figure 45. Watchlist of upcoming biologic LOEs and candidate developers
Figure 46. Evidence requirements across the biosimilar lifecycle in Japan
Figure 47. Commercial-infrastructure requirements for a Japan biosimilar launch
Figure 48. Framework for evaluating biosimilar entry attractiveness by molecule
Figure 49. Key-question tree for investors in the Japan biosimilar theme
Figure 50. Japan biosimilar policy and market event calendar, 2025-2027

Biosimilars: The Eylea Loss-of-Exclusivity Case | Policy & Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Biosimilars: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures